Loading the company…
Loading the company…
Families: Pacemaker, ICD & CRT implantation, CGM & insulin pump management, Spinal cord & DRG stimulation, Peripheral nerve stimulation & intrathecal pumps, Coronary intervention (PCI), Lumbar fusion, DBS & VNS, Incontinence, prolapse & sacral neuromodulation, EP ablation, Structural heart (TAVR, TEER), Aortic endografts (EVAR/TEVAR), Mechanical circulatory support and 28 more.
All companies · Product and company coverage
Intersect ENT's surgeons now deal with Medtronic. Integration brings new reps, contracts and bundles: for a competitor, a window while it settles; for Medtronic, surgeons to keep.
Medtronic press release · closing date to confirm
Payments and FDA records read by the company that owns the business today, so a deal never looks like surgeons switching; a surgeon’s payment history still shows the name each payment was made under.
In the last ten years FDA made 4,801 decisions for Medtronic (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 39 procedure families, the most in 2018 (641). The latest was on 2026-10-16.
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-10-16 | 510(k) | K262443 | Transorb Self-Gripping Resorbable Mesh (TSB1510 / TSB2020 / TSB3030 / TSB4030) |
| 2026-10-16 | PMA | P860004-S462 | SynchroMed Infusion System, Ascenda Intrathecal Catheters · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-10-16 | PMA | P060001-S059 | Protégé GPS Self-Expanding Peripheral Stent System; Protégé RX Self-Expanding Carotid Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-10-16 | PMA | P030045-S011 | Visi-Pro balloon-Expandable peripheral stent system · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-10-16 | PMA | P110023-S069 | EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Medtronic.
In 2025, Medtronic reported engagement with 75,096 surgeons and other clinicians in the states MedaRep covers, worth $41M in consulting, speaking, meals and travel for its device products, the most in California ($4.5M to 5,867). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($4.5M, 5,867 engaged), Texas ($3.4M, 7,715 engaged), New York ($2.9M, 4,697 engaged), Pennsylvania ($2.8M, 3,407 engaged), Florida ($2.7M, 6,396 engaged).